WO2004056306A2 - Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen - Google Patents
Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen Download PDFInfo
- Publication number
- WO2004056306A2 WO2004056306A2 PCT/DE2003/004204 DE0304204W WO2004056306A2 WO 2004056306 A2 WO2004056306 A2 WO 2004056306A2 DE 0304204 W DE0304204 W DE 0304204W WO 2004056306 A2 WO2004056306 A2 WO 2004056306A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dopa
- derivatives
- physiologically tolerable
- tolerable salts
- prophylaxis
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title claims abstract description 35
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 208000028017 Psychotic disease Diseases 0.000 title claims abstract description 16
- 238000011321 prophylaxis Methods 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 title description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 108010035075 Tyrosine decarboxylase Proteins 0.000 claims abstract description 10
- 239000002532 enzyme inhibitor Substances 0.000 claims abstract description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 9
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims description 10
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical group OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 9
- 239000003954 decarboxylase inhibitor Substances 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 6
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims description 5
- 229960000911 benserazide Drugs 0.000 claims description 5
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 4
- -1 2, 3, 4-trihydroxybenzyl Chemical group 0.000 claims description 4
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 4
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims description 4
- 229960004596 cabergoline Drugs 0.000 claims description 4
- XMRLUNALKLDUPT-UHFFFAOYSA-L calcium;5-butylpyridine-2-carboxylate Chemical group [Ca+2].CCCCC1=CC=C(C([O-])=O)N=C1.CCCCC1=CC=C(C([O-])=O)N=C1 XMRLUNALKLDUPT-UHFFFAOYSA-L 0.000 claims description 4
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 4
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical group CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 4
- 229960003741 tranylcypromine Drugs 0.000 claims description 4
- BNQDCRGUHNALGH-LURJTMIESA-N (2s)-2-amino-3-hydroxy-n'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide Chemical compound OC[C@H](N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-LURJTMIESA-N 0.000 claims description 3
- VEWUMDXDCNJDHA-UHFFFAOYSA-N 2-amino-n'-[(2,3,4-trihydroxyphenyl)methyl]acetohydrazide Chemical compound NCC(=O)NNCC1=CC=C(O)C(O)=C1O VEWUMDXDCNJDHA-UHFFFAOYSA-N 0.000 claims description 3
- 229940122439 Hydroxylase inhibitor Drugs 0.000 claims description 3
- ATBFLBIXSWKADE-UHFFFAOYSA-L calcium;5-pentylpyridine-2-carboxylate Chemical compound [Ca+2].CCCCCC1=CC=C(C([O-])=O)N=C1.CCCCCC1=CC=C(C([O-])=O)N=C1 ATBFLBIXSWKADE-UHFFFAOYSA-L 0.000 claims description 3
- 229960004205 carbidopa Drugs 0.000 claims description 3
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 3
- 229960003337 entacapone Drugs 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004644 moclobemide Drugs 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical group C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 3
- 229960003946 selegiline Drugs 0.000 claims description 3
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 claims description 2
- 239000003697 methyltransferase inhibitor Substances 0.000 claims description 2
- 229940123379 Methyltransferase inhibitor Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- BUZLUQORXILCMY-LBPRGKRZSA-N (2s)-2-amino-3-(4-hydroxyphenyl)-n'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide Chemical compound C([C@H](N)C(=O)NNCC=1C(=C(O)C(O)=CC=1)O)C1=CC=C(O)C=C1 BUZLUQORXILCMY-LBPRGKRZSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 3
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 2
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- VIKKBVWEWMBLAT-UHFFFAOYSA-N calcium;pentyl pyridine-2-carboxylate Chemical compound [Ca].CCCCCOC(=O)C1=CC=CC=N1 VIKKBVWEWMBLAT-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940087613 comtan Drugs 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960003678 selegiline hydrochloride Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical group COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- L-DOPA L-DOPA
- its derivatives and medicaments containing these compounds for the prophylaxis of psychotic diseases
- the invention relates to the use of 3, 4-dihydroxy-L-phenylalanine (L-DOPA) and its derivatives for the manufacture of medicaments and their use for the prophylaxis of psychotic diseases and for the treatment of diseases caused by disturbed tyrosine transport or tyrosine decarboxylase become.
- L-DOPA 3, 4-dihydroxy-L-phenylalanine
- L-DOPA is usually administered in drugs with active additives.
- combinations of L-DOPA with peripheral decarboxylase inhibitors with inhibitors of catechol-O-methyltransferase (COMT), with inhibitors of monoamine oxidase (MAO) and inhibitors for dopamine- ⁇ -hydroxylase are used.
- CCT catechol-O-methyltransferase
- MAO monoamine oxidase
- Calcium 5-butylpicolinate and calcium 5-pentylpicolinate are described as inhibitors for dopamine- ⁇ -hydroxylase (DE-A 2 049 115).
- L-DOPA can be used for the prophylaxis of psychotic diseases. This is all the more astonishing since psychotic disorders are known as side effects with high doses of L-DOPA.
- L-DOPA L-DOPA
- its derivatives and their physiologically tolerable salts in combination with an enzyme inhibitor or several enzyme inhibitors for the prophylaxis of psychotic diseases and for the treatment of diseases caused by disturbed tyro- sintransport or disturbed tyrosine decarboxylase.
- composition in which the enzyme inhibitor or the enzyme inhibitors are decarboxylase inhibitors and / or catechol-O-
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004561055A JP2006511558A (ja) | 2002-12-19 | 2003-12-18 | 精神病疾患を予防するためのｌ−ドーパ、その誘導体およびこれらの化合物を含有する医薬品の使用 |
| CA002513077A CA2513077A1 (en) | 2002-12-19 | 2003-12-18 | Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases |
| AU2003294664A AU2003294664A1 (en) | 2002-12-19 | 2003-12-18 | Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases |
| US10/539,793 US20070082953A1 (en) | 2003-12-18 | 2003-12-18 | Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases |
| MXPA05006409A MXPA05006409A (es) | 2002-12-19 | 2003-12-18 | Uso de l-dopa, de sus derivados y medicamentos comprendiendo estos compuestos para la prevencion de enfermedades psicoticas. |
| EP03785594A EP1615631A2 (de) | 2002-12-19 | 2003-12-18 | Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen |
| EA200500957A EA200500957A1 (ru) | 2002-12-19 | 2003-12-18 | Применение l-допа, его производных и лекарственных средств, содержащих эти соединения, для профилактики психотических заболеваний |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10261808.9 | 2002-12-19 | ||
| DE10261808A DE10261808A1 (de) | 2002-12-19 | 2002-12-19 | Verwendung von L-DOPA, seiner Derivate und diese Verbindungen enthaltender Arzneimittel zur Prophylaxe psychotischer Erkrankungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004056306A2 true WO2004056306A2 (de) | 2004-07-08 |
| WO2004056306A3 WO2004056306A3 (de) | 2004-11-11 |
Family
ID=32478131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/DE2003/004204 WO2004056306A2 (de) | 2002-12-19 | 2003-12-18 | Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1615631A2 (es) |
| JP (1) | JP2006511558A (es) |
| CN (1) | CN1756542A (es) |
| AU (1) | AU2003294664A1 (es) |
| CA (1) | CA2513077A1 (es) |
| DE (1) | DE10261808A1 (es) |
| EA (1) | EA200500957A1 (es) |
| MX (1) | MXPA05006409A (es) |
| PL (1) | PL377524A1 (es) |
| WO (1) | WO2004056306A2 (es) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007093450A2 (en) * | 2006-02-17 | 2007-08-23 | Birds Pharma Gmbh Berolina Innovative Research & Development Services | Deuterated catecholamine derivatives and medicaments comprising said compounds |
| JP2008505966A (ja) * | 2004-07-12 | 2008-02-28 | ディズリン・メディカル・デザイン・アクチボラゲット | レボドパの輸液および注射液 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105078952A (zh) * | 2015-08-10 | 2015-11-25 | 中国康复研究中心 | 一种左旋多巴制剂及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2001060A (en) * | 1977-07-01 | 1979-01-24 | Merrell Toraude & Co | alpha -Acetylenic Amino Acids |
| US5330895A (en) * | 1989-10-12 | 1994-07-19 | Ramirez Victor D | Detection reagent and antibody specific for dopamine releasing protein |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52102431A (en) * | 1976-02-25 | 1977-08-27 | Kyowa Hakko Kogyo Co Ltd | Remedies for mental disorder |
-
2002
- 2002-12-19 DE DE10261808A patent/DE10261808A1/de not_active Ceased
-
2003
- 2003-12-18 PL PL377524A patent/PL377524A1/pl not_active Application Discontinuation
- 2003-12-18 WO PCT/DE2003/004204 patent/WO2004056306A2/de not_active Application Discontinuation
- 2003-12-18 JP JP2004561055A patent/JP2006511558A/ja active Pending
- 2003-12-18 AU AU2003294664A patent/AU2003294664A1/en not_active Abandoned
- 2003-12-18 EP EP03785594A patent/EP1615631A2/de not_active Withdrawn
- 2003-12-18 CA CA002513077A patent/CA2513077A1/en not_active Abandoned
- 2003-12-18 CN CNA2003801066148A patent/CN1756542A/zh active Pending
- 2003-12-18 MX MXPA05006409A patent/MXPA05006409A/es unknown
- 2003-12-18 EA EA200500957A patent/EA200500957A1/ru unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2001060A (en) * | 1977-07-01 | 1979-01-24 | Merrell Toraude & Co | alpha -Acetylenic Amino Acids |
| US5330895A (en) * | 1989-10-12 | 1994-07-19 | Ramirez Victor D | Detection reagent and antibody specific for dopamine releasing protein |
Non-Patent Citations (5)
| Title |
|---|
| DATABASE WPI Section Ch, Week 198401 Derwent Publications Ltd., London, GB; Class B05, AN 1984-001816 XP002278318 & JP 47 030824 A (KYOWA HAKKO KOGYO KK) 10. November 1972 (1972-11-10) * |
| GERLACH J ET AL: "The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo." PSYCHOPHARMACOLOGIA. GERMANY, WEST 14 OCT 1975, Bd. 44, Nr. 1, 14. Oktober 1975 (1975-10-14), Seiten 105-110, XP008030065 ISSN: 0033-3158 * |
| HALE M S ET AL: "LOW DOSE PERPHENAZINE AND LEVODOPA/CARBIDOPA THERAPY IN A PATIENT WITH PARKINSONISM AND A PSYCHOTIC ILLNESS" JOURNAL OF NERVOUS AND MENTAL DISEASE, WILLIAMS AND WILKINS, US, Bd. 168, Nr. 5, 1980, Seiten 312-314, XP008020514 ISSN: 0022-3018 * |
| SANDOR, PAUL ET AL: "Remoxipride in the treatment of levodopa-induced psychosis" JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (1996), 16(5), 395-399, XP008030094 * |
| See also references of EP1615631A2 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008505966A (ja) * | 2004-07-12 | 2008-02-28 | ディズリン・メディカル・デザイン・アクチボラゲット | レボドパの輸液および注射液 |
| JP2013028609A (ja) * | 2004-07-12 | 2013-02-07 | Dizlin Medical Design Ab | レボドパの輸液および注射液 |
| US8735382B2 (en) | 2004-07-12 | 2014-05-27 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| JP2015227341A (ja) * | 2004-07-12 | 2015-12-17 | ディズリン・メディカル・デザイン・アクチボラゲットＤｉｚｌｉｎ Ｍｅｄｉｃａｌ Ｄｅｓｉｇｎ Ａｂ | レボドパの輸液および注射液 |
| US9248113B2 (en) | 2004-07-12 | 2016-02-02 | Dizlin Medical Design Ab | Infusion and injection solution of Levodopa |
| WO2007093450A2 (en) * | 2006-02-17 | 2007-08-23 | Birds Pharma Gmbh Berolina Innovative Research & Development Services | Deuterated catecholamine derivatives and medicaments comprising said compounds |
| WO2007093450A3 (en) * | 2006-02-17 | 2007-09-27 | Birds Pharma Gmbh Berolina Inn | Deuterated catecholamine derivatives and medicaments comprising said compounds |
| US8247603B2 (en) | 2006-02-17 | 2012-08-21 | Birds Pharma Gmbh Berolina Innovative | Deuterated catecholamine derivatives and medicaments comprising said compounds |
| EA017983B1 (ru) * | 2006-02-17 | 2013-04-30 | Бедс Фарма Гмбх Беролина Инновейтив Ресёч Энд Девелопмент Сёвисиз | Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения |
| EP3101001A1 (en) * | 2006-02-17 | 2016-12-07 | ratiopharm GmbH | Deuterated catecholamine derivatives and medicaments comprising said compounds |
| USRE46555E1 (en) | 2006-02-17 | 2017-09-19 | Teva Pharmaceuticals International Gmbh | Deuterated catecholamine derivatives and medicaments comprising said compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006511558A (ja) | 2006-04-06 |
| EA200500957A1 (ru) | 2006-02-24 |
| CA2513077A1 (en) | 2004-07-08 |
| EP1615631A2 (de) | 2006-01-18 |
| WO2004056306A3 (de) | 2004-11-11 |
| CN1756542A (zh) | 2006-04-05 |
| PL377524A1 (pl) | 2006-02-06 |
| DE10261808A1 (de) | 2004-07-08 |
| MXPA05006409A (es) | 2006-05-31 |
| AU2003294664A1 (en) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1248606B1 (de) | Verwendung von fumarsäurederivaten zur behandlung mitochondrialer krankheiten | |
| EP1907386B1 (de) | Aminosäuresalze von rosiglitazon | |
| EP1305300A1 (de) | Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
| DE2817358A1 (de) | Neue therapeutische anwendung von acylderivaten des d,l-carnitin | |
| WO2002102743A9 (de) | Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel | |
| EP1613571B1 (de) | Deuterierte catecholaminderivate sowie diese verbindungen enthaltende arzneimittel | |
| DE102005014080B4 (de) | Additionssalze des Tolperison, Verfahren zu deren Herstellung, Verwendung derselben und diese enthaltende Arzneimittel | |
| EP0132811A1 (de) | In 1-Stellung substituierte 4-Hydroxymethyl-pyrrolidinone, Verfahren zu ihrer Herstellung, pharmazeutische Zusammensetzungen und Zwischenprodukte | |
| EP1615631A2 (de) | Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen | |
| DE2460929C2 (es) | ||
| DE2405094A1 (de) | 2-aminoindan-abkoemmlinge, deren herstellung und verwendung | |
| EP0471388B1 (de) | Mittel zur Behandlung der Herzinsuffizienz | |
| EP0951907A1 (de) | Verwendung von Moxonidin alsThermogenese stimulierend wirksame Arzneimittel | |
| EP0147707A2 (de) | 1,7-Diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur Verwendung bei der Bekämpfung von Krankheiten | |
| DE10312809A1 (de) | Pramipexol zur Reduzierung übermäßiger Nahrungsaufnahme bei Kindern | |
| EP0489043B1 (de) | Verwendung des (+)-enantiomeren von anipamil | |
| DE2207460C2 (de) | Verwendung von Hydroxycylohexylaminderivaten bei der Behandlung von ödematös atelektatischen Lungenveränderungen | |
| EP0669826A1 (de) | (-)-metrifonat enthaltendes arzneimittel | |
| EP0005732A1 (de) | Verwendung von 2-Amino-oxazolo- oder 2-Amino-thiazolo-[5,4-d]azepinen sowie deren Säureadditionssalzen zur Herstellung eines Arzneimittels für die Verwendung bei der Bekämpfung von Angina Pectoris | |
| US20070082953A1 (en) | Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases | |
| AT396427B (de) | Pharmazeutische verwendung eines oxipurinolsalzes | |
| EP0025069B1 (de) | Neues Pentylspartein-Salz, dieses enthaltendes Arzneimittel und Verfahren zur Herstellung eines solchen Arzneimittels | |
| EP0109622A1 (de) | 7-Phenyl-7-phenoxymethyl-hexahydro-1,4-oxazepine, ihre Herstellung und Verwendung | |
| DE2336560B1 (de) | Arzneimittel, enthaltend 1-(2-hydroxy2-indanyl)-propylamin | |
| DE1793799C2 (de) | 1 -Phenoxy^-hydroxyO-alkylaminopropane, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 377524 Country of ref document: PL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/006409 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 169204 Country of ref document: IL Ref document number: 2004561055 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 20038A66148 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003785594 Country of ref document: EP Ref document number: 541048 Country of ref document: NZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003294664 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2513077 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200500957 Country of ref document: EA |
|
| WWP | Wipo information: published in national office |
Ref document number: 2003785594 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007082953 Country of ref document: US Ref document number: 10539793 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 10539793 Country of ref document: US |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2003785594 Country of ref document: EP |